Xspray Pharma AB (publ) (XSPRAY.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-09-08). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. XSPRAY.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 32.57% | 30.00% | Fail |
| Interest-bearing investments | 33.75% | 30.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.29% | 33.00% | Pass |
| Interest-bearing investments | 19.98% | 33.00% | Pass |
| Non-liquid assets | 79.52% | at least 20.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.29% | 33.33% | Pass |
| Cash + interest-bearing securities | 19.98% | 33.33% | Pass |
| Accounts receivable | 20.48% | 33.33% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.29% | 33.33% | Pass |
| Cash + interest-bearing securities | 19.98% | 33.33% | Pass |
| Accounts receivable | 20.48% | 50.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.52% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.90% | 33.00% | Pass |
| Accounts receivable | 0.27% | 33.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.02% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.38% | 49.00% | Pass |
| Accounts receivable | 0.26% | 49.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.02% | 33.33% | Pass |
| Cash + interest-bearing securities | 10.38% | 33.33% | Pass |
| Accounts receivable | 10.64% | 49.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 24.50 | BUY |
| Stochastic %K (14) | 7.20 | BUY |
| CCI (20) | -78.17 | NEUTRAL |
| Williams %R (14) | -92.80 | BUY |
| MACD (12,26,9) | 0.09 | BUY |
| ROC (10) | -5.86 | SELL |
| Momentum (10) | -0.60 | SELL |
| EMA (10) | 10.05 | SELL |
| SMA (10) | 9.93 | SELL |
| EMA (20) | 10.88 | SELL |
| SMA (20) | 10.67 | SELL |
| EMA (30) | 11.72 | SELL |
| SMA (30) | 12.12 | SELL |
| EMA (50) | 13.29 | SELL |
| SMA (50) | 13.45 | SELL |
| EMA (100) | 16.75 | SELL |
| SMA (100) | 17.53 | SELL |
| EMA (200) | 22.45 | SELL |
| SMA (200) | 22.54 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2024-12-31, figures in SEK.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.